Question special
Lead Moderator

The CANTOS paper did not include subgroup analysis, but it is interesting to consider the possibility that certain patient populations may benefit from canakinumab more or less than others (e.g. smokers, diabetics, male vs female, etc). Which populations are likely to benefit most? Or do you believe benefit is best predicted only by extent of hs-CRP elevation? Why?